ArticleBMJ open2023

Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol.

Tobias Freyberg Justesen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.